Patients with advanced-stage hormone receptor-positive (HR+) breast cancer typically receive first-line treatment with anti-oestrogen-based agents, often combined with a CDK4/6 inhibitor, although resistance remains common. The authors of this Review discuss how a variety of novel endocrine therapies together with tumour molecular profiling could shape the future therapeutic landscape for these patients.
- Maxwell R. Lloyd
- Komal Jhaveri
- Seth A. Wander
